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Palliative chemotherapy for inoperable/metastatic oesophageal cancer has limited activity. This study assesses the feasibility and
activity of gemcitabine and cisplatin in this group of patients. In total, 42 patients with locally advanced/metastatic squamous or
adenocarcinoma of the oesophagus were treated with gemcitabine 1250mgm
 2 days 1 and 8 and cisplatin 75mgm
 2 day 1 in a 21-
day cycle. Interim safety analysis was carried out after the first 19 patients suggested significant toxicity. The dose of gemcitabine was
subsequently reduced to 1000mgm
 2. Patients were assessed for toxicity and response. The median number of treatment cycles
per patient was 4 (range 1–6). Grade 3–4 neutropenia occurred in 37% of cycles; however, there was only one episode of
neutropenic fever. Nonhaematological toxicities included fatigue, nausea and vomiting. Among 32 patients eligible for response, there
were three complete responses and 16 partial responses (overall response rate of 45%); nine patients had stable disease. Median
survival was 11 months. The response rate appears to be greatest in those with squamous carcinoma compared to adenocarcinoma
(71 vs 33%, P¼0.036). The combination of gemcitabine and cisplatin in this schedule has manageable toxicity and significant activity in
patients with locally advanced/metastatic oesophageal cancer and is worthy of further study.
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Oesophageal cancer is the ninth most common cancer worldwide.
In the UK, the incidence ranges from 13 to 17 per 100000 for male
and around six per 100000 for female subjects. It is locally
advanced/unresectable or metastatic at the time of diagnosis in
around 80% patients. Of these, approximately 80% will die within
12 months from diagnosis. The overall 5-year survival is 5%. Over
the past 15 years, the incidence of adenocarcinoma of the
oesophagus has increased, while that of squamous carcinoma has
reduced. It is, however, unclear whether a difference exists in the
natural history, sensitivity to treatment or prognosis between
these.
Two of the most active agents in single agent phase II trials are
cisplatin and 5-fluorouracil (5-FU) (Alberts et al, 1992; Bleiberg
et al, 1997). In combination, these have a response rate of 25–35%
in locally advanced or metastatic squamous cell carcinoma of the
oesophagus (Bleiberg et al, 1997). Despite this activity, there is a
pressing need to develop new regimens to improve the response
and lessen the toxicity of treatment, thereby optimising quality of
life in these patients treated with palliative intent.
Gemcitabine (20,2 0-difluoro-20-deoxycytidine) is a nucleoside
analogue, which inhibits ribonuclease reductase. Its triphosphate
metabolite is also incorporated into DNA resulting in premature
termination of replicating DNA strands. The major dose-limiting
toxicity of gemcitabine is myelosuppression (Abbruzzese et al,
1991); however, this is rarely complicated. Gemcitabine is active
against a broad range of tumour types including non-small-cell
lung cancer (NSCLC) (Anderson et al, 1994), small-cell lung cancer
(Cornier et al, 1994), breast cancer (Possinger, 1995), head and
neck cancer (Catimel et al, 1994), pancreatic cancer (Burris et al,
1997), bladder cancer (Stadler et al, 1997) and ovarian cancer
(Lund et al, 1994).
In preclinical models, gemcitabine reduces resistance to
cisplatin and exhibits synergy with cisplatin (Braakhuis et al,
1995; Rose et al, 2003). This appears to be sequence dependent
(Peters et al, 1995; Bergman et al, 1996; Crul et al, 2003); however,
there is no consensus on the optimal schedule in vivo. The
combination of gemcitabine and cisplatin has been evaluated in
NSCLC (Steward et al, 1996; Rinaldi et al, 2000; Huisman et al,
2001; Rossi et al, 2002; Soto Parra et al, 2002). The cisplatin dose
ranges from 50mgm
 2 on days 1 and 8 to 100mgm
 2 given on
day 1 or 2. The gemcitabine dose ranges from 800 to 1250mgm
 2
weekly for 2 out of 3 or 3 out of 4 weeks. In NSCLC, the use of a 3
weekly regimen results in significantly fewer dose delays and
reductions (19 vs 51%), improved dose intensity, similar response
rates and reduced grade 3/4 thrombocytopenia (6 vs 30%) than a 4
weekly one. This combination has also been tested in ovarian
cancer (Nogue et al, 2002), transitional cell carcinoma (Lorusso
et al, 2000) and pancreatic cancer. In the latter, a response rate of
11% was observed with stable disease in 57% (Heinemann et al,
2000). The major toxicities are haematological with grade
3/4 leucopoenia in approximately 30% and thrombocytopenia in
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s5–30% patients. The most frequent nonhaematological toxicities
are asthenia, nausea and vomiting and occasional alopecia. Minor
degrees of neurotoxicity and transient disturbances in renal
function are occasionally observed.
In view of the synergy between these two drugs and the
manageable toxicity of the combination, this trial was undertaken
to assess its activity in oesophageal carcinoma.
PATIENTS AND METHODS
Ethics
Ethical approval was granted by the local research ethics
committee in each of the participating centres.
Eligibility
Patients with locally advanced, unresectable or metastatic,
histologically proven, squamous or adenocarcinoma of the
oesophagus with bidimensionally measurable disease, ECOG
performance status 0–2, life expectancy of 43 months, adequate
liver, kidney and bone marrow function were eligible. Prior
chemotherapy for metastatic disease was not allowed, although
patients who had received neoadjuvant or adjuvant therapy were
considered eligible if this had been completed more than 12
months prior to study entry. Patients with a previous history of
malignancy with the exception of in situ carcinoma of the uterine
cervix or nonmelanotic skin cancer were excluded. All participants
gave written informed consent before entry.
Patient assessment and response evaluation
Pretreatment evaluation included a full medical history and
examination, full blood count and biochemical profile including
urea, electrolytes, and liver function tests and baseline radiological
disease assessment. Response was assessed according to the World
Health Organisation Criteria. To be evaluable for response,
patients had to complete at least three cycles of chemotherapy;
however, response rates are calculated by intention to treat. All
patients receiving chemotherapy were included in the safety
analysis. Toxicity was graded according to the National Cancer
Institute common toxicity criteria version 2.
Treatment
Cisplatin 75mgm
 2 in 1l normal saline over 4h with pre- and
posthydration was given on day 1. Gemcitabine was given at a dose
of 1250mgm
 2 in 250ml normal saline over 30min on days 1 and
8. Treatment was repeated every 21 days. After interim analysis of
the first 19 patients, the gemcitabine dose was reduced to
1000mgm
 2. Antiemetics were administered according to stan-
dard practice at each of the participating centres.
Dose modification
For a calculated creatinine clearance of 40–60mlmin
 1, the dose
of cisplatin was split and administered on two consecutive days.
Cisplatin was omitted if the calculated creatinine clearance was less
than 40mlmin
 1. Cisplatin was discontinued in the event of grade
3 or worse peripheral neuropathy. Following interim analysis, any
patient experiencing other non-haematological toxicity (with the
exception of alopecia and inadequately controlled nausea and
vomiting) of grade 3 or above had a dose reduction of 25% in
subsequent cycles. Modifications for haematological toxicity are
shown Table 1.
Statistics
Using Flemings one stage design, 48 patients were required to
detect a response rate of 40–60% with a power of 80% at the 5%
significance level. The Kaplan–Meier survival curves were
generated using SPSS for Windows version 11.5 (Lead Technol-
ogies Inc., Charlotte N.C.). Following initial analysis of toxicity in
the first 19 patients, it was decided to reduce the total number of
patients recruited to 42 as this would not significantly affect the
power of the trial, but would have reduced the number of patients
exposed to significant toxicity if the toxicity profile was not
improved in the second cohort of patients.
RESULTS
Demographic data
Between March 2000 and August 2003, 42 patients were recruited;
one from Glasgow, 16 from Edinburgh and 25 from Belfast. Patient
characteristics are shown in Table 2.
An interim analysis was performed after the first 19 patients
were enrolled due to concerns over the level of toxicity. This
resulted in a reduction of gemcitabine dose as described
previously.
A total of 182 cycles of chemotherapy were completed. All
patients received at least one dose of chemotherapy and were
therefore eligible for the safety analysis. The median number of
cycles received was 4 with a range of 1–6. For the first 19 patients,
the median number of cycles was 4; seven patients (37%)
completed six cycles and six (32%) patients withdrew due to
toxicity. Following amendment of the gemcitabine dose, the
Table 1 Dose modifications for haematological toxicity
Days ANC Plts % Full dose
Preamendment
1 and 8 X1 10
9l
 1 AND 4100 10
9l
 1 100
1 and 8 0.5–0.9 10
9l
 1 OR 50–99 10
9l
 1 50
1 and 8 o0.5 10
9l
 1 OR o50 10
9l
 1 Nil
Postamendment
1 X1.5 10
9l
 1 AND 4100 10
9l
 1 100
1 o1.5 10
9l
 1 OR o100 10
9l
 1 Delay until recovery
8 X1.5 10
9l
 1 AND 4100 10
9l
 1 100
8 1–1.5 10
9l
 1 OR 50–100 10
9l
 1 50
8 o1 10
9l
 1 OR o50 10
9l
 1 Omit
ANC¼absolute neutrophil count; Plts¼platelets.
Table 2 Demographic data
Median age (range) 60 (37–79) years
Male:female 34:8
Performance status
01 3
12 2
25
Unrecorded 2
Histology
Squamous 14
Adeno 27
Mixed 1
Stage
Locally advanced 3
Metastatic 39
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smedian number of cycles was six; 13 patients (57%) completed six
cycles and three (13%) patients withdrew due to toxicity. There
was no significant difference in the delivered dose intensity pre-
and postamendment.
There was significant haematological toxicity prior to the
amendment. This was by the reduction of gemcitabine dose to
1000mgm
 2. Haematological toxicity is summarised in Table 3.
There was one episode of neutropenic fever.
The major non-haematological toxicities were fatigue, nausea
and vomiting. Grade 3–4 fatigue occurred in 13 patients (31%).
Grade 3–4 nausea and vomiting occurred in seven patients (37%)
and 13% of administered treatment cycles preamendment and
three patients (13%) and 3% of treatment cycles postamendment.
One patient experienced treatment related renal impairment.
Grade 1–2 peripheral neuropathy occurred in 10 patients, and
grade 1 tinnitus in five patients. Non-haematologic toxicity is
summarised in Table 4.
Two patents suffered cerebrovascular accidents and one patient
experienced a subendocardial infarct. There were two episodes
each of haematemesis and melaena; one such patient died of a GI
bleed despite aggressive resuscitation.
A total of 32 patients were evaluable for response. Three were
unevaluable because they had clinical progression after two cycles,
three withdrew early due to toxicity. One patient died of a GI
haemorrhage after cycle 1. Two patients suffered cerebrovascular
accidents and one a subendocardial infarct. Three complete
responses (7%) and 16 partial responses (38%) were observed
giving an overall response rate of 45% by intention to treat. The
response rate among evaluable patients was 59%. Nine patients
(21%) had stable disease and four (10%) progressed on treatment.
Median survival was 11 months (95% CI 4.8–17.3 months).
(Figure 1).
Three patients recruited to the study had locally advanced
inoperable disease. All three were rendered operable by che-
motherapy and are still alive at 47, 44 and 30 months from the
commencement of chemotherapy. The three patients with a
complete response all had squamous carcinoma. The response
rate for squamous carcinoma is significantly higher than for
adenocarcinoma (71 vs 33%, P¼0.036 Fishers exact test).
Following treatment failure, five patients received further
chemotherapy treatment. One patient received a combination of
irinotecan with 5-FU and folinic acid and the others received a
combination of 5-FU, doxorubicin and mitomycin-c.
DISCUSSION
The prognosis of oesophageal cancer remains poor. In patients
with advanced/unresectable or metastatic disease, response rates of
25–35% are achieved with cisplatin/5FU; however, responses are
short-lived and translate into only a small improvement in
survival.
Since this study commenced, several trials have examined
gemcitabine in the treatment of advanced oesophageal cancer. A
phase II trial of single agent gemcitabine in metastatic oesophageal
cancer showed no activity in the 21 patients treated (Sandler et al,
2000). The Southwest Oncology Group conducted a multicentre
phase II trial of gemcitabine 1000mgm
 2 on days 1, 8 and 15, and
cisplatin 100mgm
 2 on day 15 of a 28-day cycle in 64 patients with
advanced oesophageal cancer. Treatment was well tolerated, with
grade 3/4 neutropenia reported in 31% patients. Median survival
was 7.3 months with a 1-year survival of 20% (Urba et al, 2004).
A further phase II study used cisplatin 50mgm
 2 on days 1 and
8 followed by gemcitabine 800mgm
 2 on days 2, 9 and 16 every 28
days in 36 patients with advanced oesophageal cancer. This was
myelosuppressive with grade X3 neutropenia in 83% patients
(three cases of neutropenic fever) and grade 3/4 thrombocytopenia
in 67% patients. Myelotoxicity was cumulative requiring omission
of gemcitabine on day 16 in 61% cases. A response rate of 41% was
observed with a median survival of 9.8 months. Response rates and
median survivals were comparable for squamous and adenocarci-
nomas (Kroep et al, 2004). In a phase II study of 40 chemonaı ¨ve
patients with advanced/metastatic gastric cancer, this schedule
resulted in grade 3/4 leucopenia and thrombocytopenia in 58 and
48% of patients, respectively, with omission of gemcitabine on day
16 in 55% cycles. The response rate was 30% with a median
survival of 11 months (De Lange et al, 2004).
Our study, similarly, demonstrates the activity of gemcitabine
and cisplatin in advanced oesophageal cancer. The overall
response rate of 45% and the median overall survival of 11
months are similar to other trials of this combination. The initial
dose and schedule of gemcitabine 1250mgm
 2 with cisplatin
75mgm
 2 was based on reports of the tolerability and activity in
NSCLC (Castellano et al, 1998). This regimen, however, results in
unacceptable toxicity for patients with oesophageal cancer. With a
Table 3 Haematological toxicity in all cycles
Preamendment
(n¼77 cycles)
Postamendment
(n¼105 cycles)
Grade 3 Grade 4 Grade 3 Grade 4
n (%) n (%) n (%) n (%)
Neutropenia 25 (32) 14 (18) 27 (26) 2 (2)
Thrombocytopenia 13 (17) 0 17 (16) 0
Anaemia 1 (1) 0 3 (3) 0
Table 4 Major non-haematologic toxicity in all cycles
Pre-amendment
(n¼77 cycles)
Post-amendment
(n¼105 cycles)
Grade 2 Grade 3/4 Grade 2 Grade 3/4
n (%) n (%) n (%) n (%)
Aesthenia 21 (27) 11 (14) 16 (15) 6 (6)
Diarrhoea 2 (3) 3 (4) 1 (1) 0
Stomatitis 3 (4) 1 (1)
Nausea/vomiting 11 (14) 10 (13) 8 (8) 3 (3)
1.0
0.8
0.6
0.4
0.2
0.0
0
Survival (months)
10 20 30 40 50
C
u
m
 
s
u
r
v
i
v
a
l
survival factor
censored
Figure 1 Overall survival.
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sgemcitabine dose of 1000mgm
 2 on days 1 and 8 combined with
cisplatin 75mgm
 2 on day 1 of a 21-day cycle, toxicity is less than
that reported using more intensive schedules of administration.
This is consistent with a previous schedule-finding study, which
demonstrated that leucopoenia was schedule dependent and less
common when gemcitabine was given prior to cisplatin (Kroep
et al, 1999).
Three cerebro/cardiovascular events occurred on study. This
finding is of concern, however it should be noted that shared risk
factors make cerebro- and cardiovascular disease common
comorbidities in patients with oesophageal cancer and, as this is
a small study, no conclusions can be drawn.
In those with squamous carcinoma, the response rate was 71 vs
33% for adenocarcinoma. Although numbers are small, this
difference is statistically significant. This did not translate into
any survival difference. Previous phase II trials of cisplatin-based
regimens have suggested that the response rate for squamous
tumours is slightly higher than for adenocarcinoma (Ajani, 1994).
In those receiving neoadjuvant chemoradiotherapy for oeso-
phageal cancer, the complete pathological response rate has
been reported to be higher for squamous carcinoma than for
adenocarcinoma (44.4 vs 35.5%); however, 5-year survival rates in
these complete responders is not significantly different Makary
et al, 2003). Previous trials of gemcitabine and cisplatin in
oesophageal carcinoma have not demonstrated any difference in
response or survival by histological subtype (Kroep et al, 2004).
The activity of this combination is comparable to other platinum-
or taxane-based doublets (Ilson et al, 2000; Jatoi et al, 2002).
Our study and other recently reported trials suggest that the
combination of gemcitabine and cisplatin in oesophageal cancer is
active and worthy of further study in randomised controlled trials.
Although the response rate is not superior to other cisplatin-based
regimens, we have employed a straightforward schedule reducing
the need for hospital admission for chemotherapy administration
and the need for central venous access devices for the delivery of
infusional 5-FU.
ACKNOWLEDGEMENTS
We thank Lilly UK for supplying gemcitabine for this trial.
REFERENCES
Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B,
Mineishi S, Tarassoff P, Satterlee W, Raber MN (1991) A phase I clinical,
plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:
491–498
Ajani JA (1994) Contributions of chemotherapy in the management of
carcinoma of the oesophagus: results and commentary. Semin Oncol 21:
447–482
Alberts AS, Schoeman L, Burger W, Greef F, Falkson G (1992) A phase II
study of 5-fluorouracil and leucovorin in advanced carcinoma of the
esophagus. Am J Clin Oncol 15: 35–36
Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH (1994)
Single-agent activity of weekly gemcitabine in advanced non-small-cell
lung cancer: a phase II study. J Clin Oncol 12: 1821–1826
Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ
(1996) Synergistic interaction between cisplatin and gemcitabine in vitro.
Clin Cancer Res 2: 521–530
Bleiberg H, Conroy T, Paillot B, Lacave AJ, Blijham G, Jacob JH, Bedenne L,
Namer M, De Besi P, Gay F, Collette L, Sahmoud T (1997) Randomised
phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin
alone in advanced squamous cell oesophageal cancer. Eur J Cancer 33:
1216–1220
Braakhuis BJ, Ruiz van Haperen VW, Welters MJ, Peters GJ (1995)
Schedule-dependent therapeutic efficacy of the combination of gemci-
tabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 31:
2335–2340
Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano
MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr
FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and
clinical benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer. J Clin Oncol 15: 2403–2413
Castellano D, Lianes P, Paz-Ares L, Hidalgo M, Guerra JA, Gomez-Martin C,
Gomez H, Calzas J, Cortes-Funes H (1998) A phase II study of a novel
gemcitabine plus cisplatin regimen administered every 3 weeks for
advanced non small cell lung cancer. Ann Oncol 9: 457–459
Catimel G, Vermorken JB, Clavel M, de Mulder P, Judson I, Sessa C, Piccart
M, Bruntsch U, Verweij J, Wanders J (1994) A phase II study of
gemcitabine in patients with advanced carcinoma of the head and neck.
Ann Oncol 5: 543–547
Cornier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D,
Tarasoff P, Wong D (1994) Gemcitabine is an active agent in previously
untreated extensive small cell lung cancer. A study of the National
Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5: 283–285
Crul M, van Waardenburg RC, Bocxe S, van Eijndhoven MA, Pluim D,
Beijnen JH, Schellens JH (2003) DNA repair mechanisms involved in
gemcitabine cytotoxicity and in the interaction between gemcitabine and
cisplatin. Biochem Pharmacol 65: 275–282
De Lange SM, van Groeningen CJ, Kroep JR, Van Bochove A, Snijders JF,
Peters GJ, Pinedo HM, Giaccone G (2004) Phase II trial of cisplatin and
gemcitabine in patients with advanced gastric cancer. Ann Oncol 15:
484–488
Heinemann V, Wilke H, Mergenthaler HG, Clemens M, Konig H, Illiger HJ,
Arning M, Schalhorn A, Possinger K, Fink U (2000) Gemcitabine and
cisplatin in the treatment of advanced or metastatic pancreatic cancer.
Ann Oncol 11: 1399–1403
Huisman C, Giaccone G, van Groeningen CJ, Sutedja G, Postmus PE, Smit
EF (2001) Combination of gemcitabine and cisplatin for advanced non-
small cell lung cancer: a phase II study with emphasis on scheduling.
Lung Cancer 33: 267–275
Ilson DH, Forrastiere A, Arquette M, Costa F, Heelan R, Huang Y, Kelsen
DP (2000) A phase II trial of paclitaxel and cisplatin in patients with
advanced carcinoma of the esophagus. Cancer J 6: 316–323
Jatoi A, Tirona MT, Cha SS, Alberts SR, Rowland KM, Morton RF, Nair S,
Kardinal CG, Stella PJ, Mailliard JA, Sargent D, Goldberg RM (2002) A
phase II trial of docetaxel and CPT11 in patients with metastatic
adenocarcinoma of the esophagus, gastroesophageal junction or gastric
cardia. Int J Gastrointest Cancer 32: 115–123
Kroep JR, Peters GJ, van Moorsel CJ, Catik A, Vermorken JB, Pinedo HM,
van Groeningen CJ (1999) Gemcitabine-cisplatin: a schedule finding
study. Ann Oncol 10: 1503–1510
Kroep JR, Pinedo HM, Giaccone G, Van Bochove A, Peters GJ,
Van Groeningen CJ (2004) Phase II study of cisplatin preceding
gemcitabine in patients with advanced oesophageal cancer. Ann Oncol
15: 230–235
Lorusso V, Manzione L, De Vita F, Antimi M, Selvaggi FP, De Lena M
(2000) Gemcitabine plus cisplatin for advanced transitional cell
carcinoma of the urinary tract: a phase II multicenter trial. J Urol 164:
53–56
Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP (1994) Phase II study
of gemcitabine in previously treated ovarian cancer patients. J Natl Canc
Inst 86: 1530–1533
Makary MA, Kiernen PD, Sheridan MJ, Tonnesen G, Hetrick V, Vaughan B,
Graling P, Elster E (2003) Multimodality treatment for esophageal cancer:
the role of surgery and neoadjuvant therapy. Am Surg 69: 693–700
Nogue M, Cirera L, Arcusa A, Batiste-Alentorn E, Balil A, Font A, Perez-
Gracia JL, Carrasco EM, Tusquets I (2002) Phase II study of gemcitabine
and cisplatin in chemonaive patients with advanced epithelial ovarian
cancer. Anticancer Drugs 13: 839–845
Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM,
Braakhuis BJ (1995) Interaction between cisplatin and gemcitabine
in vitro and in vivo. Semin Oncol 22: 72–79
Possinger K (1995) Gemcitabine in advanced breast cancer. Anti-Cancer
Drugs 6: 55–59
Gemcitabine and cisplatin in oesophageal cancer
J Millar et al
1115
British Journal of Cancer (2005) 93(10), 1112–1116 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sRinaldi M, Crino L, Scagliotti GV, Mosconi AM, De Marinis F, Gridelli C,
Selvaggi G, Della Giulia M, Darwish S, Porrozzi S, Novello S, Cipri A,
Bartolucci R, Calandri C, Tonato M (2000) A three-week schedule of
gemcitabine–cisplatin in advanced non-small-cell lung cancer with two
different cisplatin dose levels: a phase II randomised trial. Ann Oncol 11:
1295–1300
Rose PG, Mossbruger K, Fusco N, Smrekar M, Eaton S, Rodriguez M (2003)
Gemcitabine reverses cisplatin resistance: demonstration of activity in
platinum-multidrug-resistant ovarian and peritoneal carcinoma. Gynecol
Oncol 88: 17–21
Rossi D, Graziano F, Catalano V, Giordani P, Fedeli SL, Alessandroni P,
Fedeli A, Dennetta D, Ugolini M, Catalano G (2002) A new cisplatin/
gemcitabine schedule in locally advanced (III) and metastatic (IV) non-
small cell lung cancer: relationship between dose-intensity and efficacy.
A phase II study. Anticancer Res 22: 3087–3092
Sandler AB, Kindler HL, Einhorn LH, Mitchell E, Masters G, Kraut M, Nicol
S, Raghavan D (2000) Phase II trial of gemcitabine in patients with
previously untreated metastatic cancer of the esophagus or gastro-
esophageal junction. Ann Oncol 11: 1161–1164
Soto Parra H, Cavina R, Latteri F, Sala A, Dambrosio M, Antonelli G,
Morenghi E, Alloisio M, Ravasi G, Santoro A (2002) Three-week versus
four-week schedule of cisplatin and gemcitabine: results of a randomised
phase II study. Ann Oncol 13: 1080–1086
Stadler WM, Kuzel T, Roth B, Raghavan D, Dorr FA (1997) Phase II study
of single-agent gemcitabine in previously untreated patients with
metastatis urothelial cancer. J Clin Oncol 15: 3394–3398
Steward WP, Dunlop DJ, Dabouis G, Lacroix H, Talbot D (1996)
Phase I/II study of gemcitabine and cisplatin in the treatment of
advanced non-small cell lung cancer: preliminary results. Semin Oncol
23: 43–47
Urba SG, Chansky K, VanVeldhuizen PJ, Pluenneke RE, Benedetti JK,
Macdonald JS, Abbruzzese JL (2004) Gemcitabine and cisplatin for
patients with metastatic or recurrent esophageal carcinoma: a Southwest
Oncology Group Study. Invest New Drugs 22: 91–97
Gemcitabine and cisplatin in oesophageal cancer
J Millar et al
1116
British Journal of Cancer (2005) 93(10), 1112–1116 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s